Physician profile
Daniel Osula
NPI 1457770851
$6,815.30
in general payments reported to CMS, 2019-2025
37 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $247 · 2021: $876 · 2022: $1,195 · 2023: $1,399 · 2024: $1,456 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,335 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,334.58 |
| Education | $163.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,197.11 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $1,146.16 | 2021-2025 | Myrbetriq, Xtandi |
| Abbvie INC. | $568.39 | 2021-2025 | |
| Antares Pharma, INC. | $517.41 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Boston Scientific Corporation | $459.39 | 2020-2024 | Lithovue, Rezum Generator, Ams 700 Cxr Rte Kit |
| Endo Pharmaceuticals INC. | $440.42 | 2020-2024 | Xiaflex, Aveed |
| Pfizer INC. | $335.56 | 2021-2025 | |
| Allergan, INC. | $191.79 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $191.42 | 2024-2025 | Adstiladrin |
| Endo USA, INC. | $174.02 | 2024-2025 | Xiaflex |
| Urogen Pharma, INC. | $169.52 | 2022-2025 | Jelmyto |
| Halozyme INC | $146.58 | 2023 | |
| Medtronic, INC. | $138.45 | 2021-2025 | Interstim |
| Myriad Genetic Laboratories, INC. | $113.87 | 2023-2024 | Prolaris |
| Myovant Sciences INC. | $91.53 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $84.19 | 2024-2025 | |
| Accord Healthcare, INC. | $72.90 | 2025 | |
| Dendreon Pharmaceuticals LLC | $71.74 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $68.59 | 2020 | |
| Janssen Biotech, INC. | $64.49 | 2024-2025 | Erleada |
| Olympus America INC. | $61.43 | 2024-2025 | Itind System, Olympus, Bovie |
| Telix Pharmaceuticals | $54.20 | 2024-2025 | Illuccix |
| Convatec INC. | $49.39 | 2021 | |
| Coloplast Corp | $47.92 | 2025 | |
| Verity Pharmaceuticals INC. | $45.84 | 2022-2023 | Trelstar |
| Conmed Corporation | $41.02 | 2021-2023 | Airseal |
| Mission Pharmacal Company | $37.88 | 2022-2023 | Uribel |
| Travere Therapeutics, INC. | $35.96 | 2020-2022 | |
| Progenics Pharmaceuticals, INC. | $35.51 | 2023-2025 | Pylarify |
| Hollister Incorporated | $30.47 | 2022 | |
| Rochester Medical Corporation | $23.63 | 2020 | |
| Merck Sharp & Dohme LLC | $21.12 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.31 | 2022 | |
| Axonics, INC. | $18.98 | 2024 | Axonics |
| Abbott Laboratories | $18.29 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.24 | 2021 | |
| Eisai INC. | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Osula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.